A Performance Comparison of Data Mining Algorithms Based Intrusion Detection System for Smart Grid

Smart grid is an emerging and promising technology. It uses the power of information technologies to deliver intelligently the electrical power to customers, and it allows the integration of the green technology to meet the environmental requirements. Unfortunately, information technologies have its inherent vulnerabilities and weaknesses that expose the smart grid to a wide variety of security risks. The Intrusion detection system (IDS) plays an important role in securing smart grid networks and detecting malicious activity, yet it suffers from several limitations. Many research papers have been published to address these issues using several algorithms and techniques. Therefore, a detailed comparison between these algorithms is needed. This paper presents an overview of four data mining algorithms used by IDS in Smart Grid. An evaluation of performance of these algorithms is conducted based on several metrics including the probability of detection, probability of false alarm, probability of miss detection, efficiency, and processing time. Results show that Random Forest outperforms the other three algorithms in detecting attacks with higher probability of detection, lower probability of false alarm, lower probability of miss detection, and higher accuracy.Comment: 6 pages, 6 Figure

Primary User Emulation Attacks: A Detection Technique Based on Kalman Filter

Cognitive radio technology addresses the problem of spectrum scarcity by allowing secondary users to use the vacant spectrum bands without causing interference to the primary users. However, several attacks could disturb the normal functioning of the cognitive radio network. Primary user emulation attacks are one of the most severe attacks in which a malicious user emulates the primary user signal characteristics to either prevent other legitimate secondary users from accessing the idle channels or causing harmful interference to the primary users. There are several proposed approaches to detect the primary user emulation attackers. However, most of these techniques assume that the primary user location is fixed, which does not make them valid when the primary user is mobile. In this paper, we propose a new approach based on the Kalman filter framework for detecting the primary user emulation attacks with a non-stationary primary user. Several experiments have been conducted and the advantages of the proposed approach are demonstrated through the simulation results.Comment: 14 pages, 9 figure

Ellagic acid: A potent glyoxalase-I inhibitor with a unique scaffold

The glyoxalase system, particularly glyoxalase-I (GLO-I), has been approved as a potential target for cancer treatment. In this study, a set of structurally diverse polyphenolic natural compounds were investigated as potential GLO-I inhibitors. Ellagic acid was found, computationally and experimentally, to be the most potent GLO-I inhibitor among the tested compounds which showed an IC50 of 0.71 mol L–1. Its binding to the GLO-I active site seemed to be mainly driven by ionic interaction via its ionized hydroxyl groups with the central Zn ion and Lys156, along with other numerous hydrogen bonding and hydrophobic interactions. Due to its unique and rigid skeleton, it can be utilized to search for other novel and potent GLO-I inhibitors via computational approaches such as pharmacophore modeling and similarity search methods. Moreover, an inspection of the docked poses of the tested compounds showed that chlorogenic acid and dihydrocaffeic acid could be considered as lead compounds worthy of further optimization

International longitudinal registry of patients with atrial fibrillation and treated with rivaroxaban: RIVaroxaban Evaluation in Real life setting (RIVER)

Background Real-world data on non-vitamin K oral anticoagulants (NOACs) are essential in determining whether evidence from randomised controlled clinical trials translate into meaningful clinical benefits for patients in everyday practice. RIVER (RIVaroxaban Evaluation in Real life setting) is an ongoing international, prospective registry of patients with newly diagnosed non-valvular atrial fibrillation (NVAF) and at least one investigator-determined risk factor for stroke who received rivaroxaban as an initial treatment for the prevention of thromboembolic stroke. The aim of this paper is to describe the design of the RIVER registry and baseline characteristics of patients with newly diagnosed NVAF who received rivaroxaban as an initial treatment. Methods and results Between January 2014 and June 2017, RIVER investigators recruited 5072 patients at 309 centres in 17 countries. The aim was to enroll consecutive patients at sites where rivaroxaban was already routinely prescribed for stroke prevention. Each patient is being followed up prospectively for a minimum of 2-years. The registry will capture data on the rate and nature of all thromboembolic events (stroke / systemic embolism), bleeding complications, all-cause mortality and other major cardiovascular events as they occur. Data quality is assured through a combination of remote electronic monitoring and onsite monitoring (including source data verification in 10% of cases). Patients were mostly enrolled by cardiologists (n = 3776, 74.6%), by internal medicine specialists 14.2% (n = 718) and by primary care/general practice physicians 8.2% (n = 417). The mean (SD) age of the population was 69.5 (11.0) years, 44.3% were women. Mean (SD) CHADS2 score was 1.9 (1.2) and CHA2DS2-VASc scores was 3.2 (1.6). Almost all patients (98.5%) were prescribed with once daily dose of rivaroxaban, most commonly 20 mg (76.5%) and 15 mg (20.0%) as their initial treatment; 17.9% of patients received concomitant antiplatelet therapy. Most patients enrolled in RIVER met the recommended threshold for AC therapy (86.6% for 2012 ESC Guidelines, and 79.8% of patients according to 2016 ESC Guidelines). Conclusions The RIVER prospective registry will expand our knowledge of how rivaroxaban is prescribed in everyday practice and whether evidence from clinical trials can be translated to the broader cross-section of patients in the real world

African Linguistics in Central and Eastern Europe, and in the Nordic Countries

Non peer reviewe

Language endangerment and language documentation in Africa

Non peer reviewe